Helping you to optimize strategy and accelerate patient access to innovative therapies
Our Latest Content
Our client wanted to improve internal understanding of financial flows occurring among health system stakeholders.
A client requested evidence-based guidance of the target product profile from both key opinion leaders (KOLs) and payers to advance their asset in product development.
A large biopharmaceutical company required insight on the current market access landscape in a rare disease, as well as feedback on a pipeline product that will launch as a second-to-market agent in the rare disease.
Regulatory, evidence, and communication strategies.
Real-World Data (RWD) have been increasingly used to further understand the natural history of a disease or condition, treatment patterns in RW practice, as well as the effectiveness, safety and costs associated with treatment options.
The US reimbursement landscape for prescription drugs has been shifting rapidly over the last few years. Some of the major US access trends that have accelerated include…
In the 2020 campaign for the US
White House, the pharmaceutical
industry had become a prime target of bipartisan outrage.
The advent of transformative
and gene therapies has amplified
affordability concerns among payers, providers and patients.
The public debate around drug pricing has spurred demand for standardized value assessment in the US
Using Certara’s Compass research network, we conducted an online survey among active voting members of P&T committees in US managed care organizations (MCOs),followed by a set of semi-structured interviews for further interpretation and probing of key trends
This is Part 1 of the ‘Succeeding in Value Communication’ series, a set of articles that examine the key success factors in creating customer engagement tools that successfully communicate the clinical and economic benefits of pharmaceuticals, devices and diagnostics.
This is Part 2 of the ‘Succeeding in Value Communication’ series, a set of articles that examine the key success factors in creating customer engagement tools that successfully communicate the clinical and economic benefits of pharmaceuticals, devices and diagnostics. These recommendations have been drawn from the experiences of the BaseCase Consulting Team.
This is Part 3 of the ‘Succeeding in Value Communication’ series, a set of articles that examine the key success factors in creating customer engagement tools that successfully communicate the clinical and economic benefits of pharmaceuticals, devices and diagnostics. These recommendations have been drawn from the experiences of the BaseCase Consulting Team.
This is Part 4 of the ‘Succeeding in Value Communication’ series, a set of articles that examine the key success factors in creating customer engagement tools that successfully communicate the clinical and economic benefits of pharmaceuticals, devices and diagnostics. These recommendations have been drawn from the experiences of the BaseCase Consulting Team.
This blog post includes key takeaways from the opening session of Certara’s first Strategic Evidence and Value Communications Symposium. This session featured the following four speakers: Shawn W. Bates is vice president of US sales and business development, Maximilian Vargas is senior director of US access strategy and account management, and Alex Solis is a senior consultant at Certara.
The global COVID-19 pandemic has affected the world in different ways, with many countries implementing lockdowns, border closures, and other movement and social restrictions. Within a very short space of time, the world went virtual.
On 2021年4月21日 (水曜日), we hosted our first annual Strategic Evidence & Value Communication Symposium. Across two panel discussions, a host of Certara and industry experts debated and explored various best practices to ensure effective communication of product value, as well as the expanded use of Real World Evidence to accelerate market access decision-making.
Securing reimbursement from national payers is critical to your product’s commercial success. However, payers at the local and regional levels continue to get more authority to manage their own budgets.
In a world of rising healthcare costs, the greatest nightmare for payers is reimbursing drug interventions that do not meaningfully benefit their covered lives.
